Literature DB >> 9287159

Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts.

L J Robinson1, W K Roberts, T T Ling, D Lamming, S S Sternberg, P D Roepe.   

Abstract

Several laboratories have reported that overexpression of the multidrug resistance (MDR) protein is associated with intracellular alkalinization, and several investigators have reported that cells induced to undergo programmed cell death (apoptosis) acidify quite significantly. Because it is difficult to fully explain the resistance to apoptosis-inducing chemotherapeutic drugs that is exhibited by MDR tumor cells solely via altered drug transport alone [Hoffman et al. (1996) J. Gen. Physiol. 108, 295-313], we have investigated whether overexpression of the hu MDR 1 protein alters progression of the apoptotic cascade. LR73 fibroblasts induced to undergo apoptosis either via treatment with the chemotherapeutic drug colchicine or by serum withdrawal exhibit cellular volume changes, intracellular acidification, nuclear condensation, and chromosomal digestion ("ladder formation"), characteristic of apoptosis, in a temporally well-defined pattern. However, multidrug resistant LR73/20E or LR73/27 hu MDR 1 transfectants recently created in our laboratory without selection on chemotherapeutic drug are significantly delayed in the onset of apoptosis as defined by the above criteria, regardless of whether apoptosis is induced by colchicine treatment or by serum withdrawal. Thus, the delay cannot simply be due to the well-known ability of MDR protein overexpression to lower chemotherapeutic drug accumulation in MDR cells. LR73/27V500 "selectants", exhibiting similar levels of MDR protein overexpression but higher multidrug resistance due to selection with the chemotherapeutic drug vincristine, exhibit a slightly longer delay in the progression of apoptosis. Normal apoptotic cascade kinetics are partially restored by pre-treatment of the MDR cells with the MDR protein inhibitor verapamil. Untransfected LR73 cells not expressing MDR protein but elevated in pHi via manipulation of CO2/HCO3- as described [Hoffman et al. (1996) J. Gen. Physiol. 108, 295-313] are inhibited in DNA ladder formation, similar to LR73/hu MDR 1 transfectants. These results uncover an additional mechanism whereby MDR protein overexpression may promote the survival of tumor cells and further support the notion that in some systems intracellular acidification may be either causal or permissive for proper progression of the apoptotic cascade.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287159     DOI: 10.1021/bi9627830

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  27 in total

1.  Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapeutic drugs.

Authors:  Bing Xiao; Yong-Quan Shi; Yan-Qiu Zhao; Han You; Zuo-You Wang; Xian-Ling Liu; Fang Yin; Tai-Dong Qiao; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.

Authors:  Y Chen; S M Simon
Journal:  J Cell Biol       Date:  2000-03-06       Impact factor: 10.539

3.  Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival.

Authors:  S Gollapud; S Gupta
Journal:  J Clin Immunol       Date:  2001-11       Impact factor: 8.317

4.  The P-glycoprotein efflux pump: how does it transport drugs?

Authors:  P D Roepe
Journal:  J Membr Biol       Date:  1998-11-01       Impact factor: 1.843

5.  A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines.

Authors:  Jessica Castro; Marc Ribó; Teresa Puig; Ramon Colomer; Maria Vilanova; Antoni Benito
Journal:  Invest New Drugs       Date:  2011-02-01       Impact factor: 3.850

Review 6.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

7.  Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway.

Authors:  Ting Chen; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Pengyuan Sun; Jinyong Peng; Zhihao Liu; Xiaobo Yang; Kexin Liu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Authors:  Jason Moore; Amy Jayne McKnight; Bernd Döhler; Matthew J Simmonds; Aisling E Courtney; Oliver J Brand; David Briggs; Simon Ball; Paul Cockwell; Christopher C Patterson; Alexander P Maxwell; Stephen C L Gough; Gerhard Opelz; Richard Borrows
Journal:  J Am Soc Nephrol       Date:  2012-10-11       Impact factor: 10.121

9.  The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy.

Authors:  Olga A Patutina; Nadezda L Mironova; Nelly A Popova; Vasily I Kaledin; Valery P Nikolin; Valentin V Vlassov; Marina A Zenkova
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

10.  ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer.

Authors:  Ewa Balcerczak; Mariusz Panczyk; Sylwester Piaskowski; Grazyna Pasz-Walczak; Aleksandra Sałagacka; Marek Mirowski
Journal:  Int J Colorectal Dis       Date:  2010-06-09       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.